EA
AIMT

Emerald Acquisition’s Aimmune Therapeutics AIMT Stock Holding History

Emerald Acquisition’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,206
Closed -$154K – 3078
2016
Q2 		$154K Buy
+14,206
New +$193K ﹤0.01% 2777

Other funds holding AIMT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
TG
TLP Group Evanston, Illinois $6.61M AUM 12.46% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Emerald Acquisition's AIMT Position: Q3 2016 in Review

Emerald Acquisition sold out of Aimmune Therapeutics (AIMT) in Q3 2016, closing a stake of 14,206 shares — an estimated $154K sold.

Emerald Acquisition first reported a position in AIMT in Q2 2016 and held it in 1 quarter. The position peaked at $154K in Q2 2016. 74 funds tracked by Wall St. Rank hold AIMT as of Q3 2016.

  • Emerald Acquisition reported no remaining Aimmune Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Emerald Acquisition sold 14,206 Aimmune Therapeutics shares in Q3 2016, an estimated $154K.
  • Emerald Acquisition first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 1 quarter.
  • Emerald Acquisition's Aimmune Therapeutics position peaked at $154K in Q2 2016.
  • 74 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.